This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Checkpoint Antibody (Agenus)
Merck & Co., Inc.
Drug Names(s): Merck Antibody
Description: Merck and Agenus are developing an antibody for an undisclosed Merck checkpoint target.
Merck and Agenus
In April 2014, Agenus entered into a collaboration and license agreement with Merck, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.
Under the terms of the agreement, Agenus is eligible to receive approximately $100 million in potential payments associated with the completion of certain clinical, regulatory and commercial milestones for two candidates from Merck. In addition, Agenus is eligible to receive royalty payments on worldwide product sales.
In June 2015, Agenus announced that Merck has extended its collaborative research term under its existing collaboration and...See full deal structure in Biomedtracker
Partners: Agenus Inc.
Checkpoint Antibody (Agenus) News
Additional information available to subscribers only: